Literature DB >> 31710879

Analysis of platelets by flow cytometry in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

David J Araten1, Daniel Boxer2, Leah Zamechek2, Erik Sherman2, Michael Nardi2.   

Abstract

The marked pro-thrombotic tendency in PNH is likely to be at least partly due to the population of platelets derived from the abnormal stem cell clone. However, identification of GPI (-) platelets by flow cytometry can be technically difficult. Here we describe a technique that involves the addition of aspirin immediately after the separation of platelet rich plasma and the use of gel filtration to isolate platelets away from plasma proteins and other blood cells. In a study of 92 analyses of samples from 50 patients, we have demonstrated that the percentage of PNH platelets correlates well with the percentage of PNH granulocytes. We also provide data on several cases where there was an extreme discrepancy between the proportion of PNH granulocytes and red cells; in these cases, the demonstration of abnormal platelets suggests that the patient is likely to be at risk of thrombosis. We believe this test will be potentially useful in the evaluation of samples from such patients and may serve as a tool to investigate the causes of hypercoagulability in PNH.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Flow cytometry; GPI; Hypercoagulability; PNH; Platelets; Thrombosis

Mesh:

Substances:

Year:  2019        PMID: 31710879     DOI: 10.1016/j.bcmd.2019.102372

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  1 in total

1.  Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria.

Authors:  Carmelo Gurnari; Amy C Graham; Alexey Efanov; Simona Pagliuca; Jibran Durrani; Hassan Awada; Bhumika J Patel; Alan E Lichtin; Valeria Visconte; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Blood Cells Mol Dis       Date:  2020-12-08       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.